How does Orgovyx (relugolix) work in the body?
Orgovyx is a treatment for advanced prostate cancer that works by blocking the androgen signaling pathway at the source. Its mechanism of action is to act as a gonadotropin-releasing hormone (GnRH) receptor antagonist in the pituitary gland. By directly blocking GnRH receptors, relugolix rapidly lowers the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which then reduces stimulation of the testes to produce testosterone. This leads to testosterone suppression, which is intended to reduce growth and survival signals in androgen-dependent prostate cancer cells.
Why does blocking GnRH lower testosterone?
Testosterone in men is largely driven by the pituitary-gonadal hormonal chain. GnRH from the hypothalamus stimulates the pituitary to release LH (and FSH). LH then signals the testes to produce testosterone. Because relugolix is a GnRH receptor antagonist, it interrupts this chain at the pituitary level, which decreases LH/FSH output and results in lower circulating testosterone.
Does Orgovyx act like a typical “hormone” therapy?
Orgovyx is not an androgen blocker that directly antagonizes the androgen receptor in cancer cells. Instead, it reduces the amount of androgen (testosterone) available by suppressing upstream hormone signaling through the GnRH receptor pathway.
What changes inside cancer cells when testosterone drops?
Prostate cancer cells that depend on androgens use testosterone (and its conversion products) to activate androgen signaling. Lower testosterone reduces androgen receptor activation, which can slow tumor growth in androgen-sensitive disease.
What is the main clinical goal of the mechanism?
The mechanism is designed to achieve androgen deprivation by lowering testosterone levels through GnRH receptor antagonism. That androgen deprivation is the therapeutic lever behind Orgovyx’s use in advanced prostate cancer.
Sources
No DrugPatentWatch.com sources were provided for the mechanism details.